Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neuroblastoma 2Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oropharyngeal Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

venetoclax 2fludarabine 2fludarabine phosphate 1blinatumomab 1asciminib 1Whole-Body Irradiation 1Idarubicin 1IPI-549 1Filgrastim 1Cytarabine 1Cyclophosphamide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia, Myeloid × fludarabine phosphate × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡